Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, has announced that its Swiss subsidiary, Glenmark Specialty SA, has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercialising its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region.

Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.

Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris™ in these markets. Menarini will be responsible for the scientific information and the commercialisation of Ryaltris™ in those markets, following regulatory approval. Glenmark will receive an upfront payment as well as launch & sales based milestone payments from Menarini for Ryaltris™ sales.

"This partnership is another step in establishing Glenmark's respiratory focus in Europe. While Glenmark will launch Ryaltris™ through its own front ends in some markets, this arrangement will allow the product to compete across Europe," said Achin Gupta, Executive Vice President, Business Head EMEA-L (Europe, Middle East, Africa, Latam) Glenmark Pharmaceuticals.